/Bill Kelly

About Bill Kelly

This author has not yet filled in any details.
So far Bill Kelly has created 1255 blog entries.

Eli Lilly set to acquire Loxo Oncology

Eli Lilly is set to acquire Loxo Oncology for approximately $8 billion. Loxo develops drugs that target cancers that have genetic mutations that can be detected by genomic testing. By targeting the DNA fingerprint of a tumor, researchers aim to treat cancer no matter where in the body tumors are found.  The company’s approach has already yielded one FDA-approved drug. In November, the U.S. regulator gave the nod to larotrectinib (Vitrakvi), a drug that treats cancers that have a mutation called a TRK fusion, which occurs in an estimated 1 percent of tumors.more

By |January 9th, 2019|News|0 Comments

BioCT welcomes new member SpringWorks

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that re-prioritizes promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer. Since its launch in 2017, SpringWorks has worked to identify, re-prioritize, and advance promising science, beginning with licensed clinical therapies from Pfizermore

By |January 9th, 2019|News|0 Comments

BioCT welcomes new member Nevivo

Nevivo is a full-service contract vivarium company with expertise to support research programs from basic housing and husbandry to model development and implementation. Located in Branford, CT, the 8,200 square feet facility is staffed with dedicated industry experts with years of experience in the pharmaceutical industry. more

By |January 9th, 2019|News|0 Comments

Yale team unlocks endosome route for biologics

“It’s been known for decades that proteins can be internalized from the cell boundary into cellular compartments known as endosomes,” says Yale’s Alanna Schepartz, Sterling Professor of Chemistry and professor of molecular, cellular & developmental biology. “Getting these molecules out of endosomes and into the cell interior was the big problem.” Schepartz and colleagues at Yale now report the identity of a molecular key that effectively unlocks the endosome, allowing the selective passage into the cell interior of potentially life-saving protein drugs.more

By |January 9th, 2019|News|0 Comments

Achillion elects Nicole Vitullo Board Chair

Achillion Pharmaceuticals reports that its Board of Directors has elected Nicole Vitullo Chair. Ms. Vitullo is a partner with Domain Associates LLC and has been a member of Achillion's Board of Directors since September 2010. As Chair, she replaces David Scheer, who has served on the Achillion Board since 1998 and was elected Chair in March 2010.  Mr. Scheer will remain on the Board of Directors.more

By |January 9th, 2019|News|0 Comments

Cybrexa selects lead candidate for solid tumors

Cybrexa Therapeutics reports that it has selected CBX-11 as its lead clinical development candidate for the treatment of patients with various solid tumors. In addition, the company announced positive feedback from its pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA), concluding that the FDA agrees with the company’s proposed IND as well as the Phase 1 clinical development plans for CBX-11.more

By |January 9th, 2019|News|0 Comments

Cara reports completion of Phase 3 trial of KORSUVA™

Cara Therapeutics has announced the completion of an interim statistical analysis of its pivotal KALM-1 Phase 3 trial of KORSUVA™ (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). “CKD-associated pruritus is a significant unmet need in patients undergoing hemodialysis, with no effective therapies approved in the United States or Europe,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “We are very pleased with the IDMC recommendation that the KALM-1 trial proceed as planned with no modifications, and we look forward to completing the study and reporting top-line data in the first [...]

By |January 9th, 2019|News|0 Comments

Melinta announces new credit facility, confirms CEO

Melinta Therapeutics reports that John H. Johnson has agreed to become the permanent chief executive officer of Melinta. Mr. Johnson is a director of Melinta and has served as interim CEO of the Company since October 22 ... more Separately, Melinta reports it has received a commitment from Vatera Healthcare Partners LLC and its affiliates for a convertible loan facility in the amount of up to of $135 million, with the option to be converted into preferred shares at an exercise price of $1.60 per share, representing a 39 percent premium to the Company’s closing share price on December 18 ... [...]

By |January 9th, 2019|News|0 Comments

Alexion receives early FDA approval for ULTOMIRIS™

The FDA has approved ULTOMIRIS™ (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells (hemolysis). “We are proud to bring ULTOMIRIS to patients suffering from this devastating disease less than a year after reporting our positive Phase 3 data,” said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion.BioCT congratulates Alexion! Their executive staff is located in Boston, but more than 450 employees are doing great [...]

By |January 9th, 2019|News|0 Comments

ABCT announces participants 2019 life sciences cohort

Accelerator for Biosciences in Connecticut has announced the second cohort of emerging biosciences ventures invited to participate in its annual program. Twelve ventures will participate in the 6.5-month-long program, which features business education to develop fundable business plans and a professional network. All startups receive an entrepreneur coach, access to active business professionals and preparation to pitch to investors.more

By |January 9th, 2019|News|0 Comments